A multidistrict litigation involving Merck & Co. shareholders claiming they were misled about heart attack risks with the drug company’s painkiller Vioxx will move forward though one claim against the company was scaled back. U.S. District Judge Stanley Chesler denied a motion by Merck to dismiss the claims saying there was insufficient evidence that the company’s statements about Vioxx risks before study data from VIGOR was released on March 27, 2000, were made with wrongful intent that would establish a securities fraud violation. VIGOR (Vioxx Gastrointestinal Outcomes Research) was a study to gauge gastrointestinal effects of Vioxx compared to naproxen, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.